Preview

Российский кардиологический журнал

Расширенный поиск

Роль бета-адреноблокаторов в терапии артериальной гипертензии в рекомендациях ESC/ESH 2018

https://doi.org/10.15829/1560-4071-2018-11-96-99

Полный текст:

Аннотация

Артериальная гипертензия (АГ) — самое часто встречающееся неинфекционное заболевание в мире и в России, ассоциированное с высокой сердечнососудистой заболеваемостью и смертностью. В августе 2018г на Европейском конгрессе кардиологов были представлены новые рекомендации по диагностике и лечению пациентов с артериальной гипертензией. В статье обсуждается роль симпатической нервной системы в патогенезе АГ и современные позиции бета­адреноблокаторов в лечении артериальной гипертензии.

Об авторах

А. О. Конради
ФГБУ Национальный медицинский исследовательский центр им. В. А. Алмазова.
Россия

д. м.н., профессор, член­корр. РАН, зам. генерального директора по научной работе, руководитель НИО артериальной гипертензии, директор Института трансляционной медицины.



Л. Г. Ратова
ФГБУ Национальный медицинский исследовательский центр им. В. А. Алмазова.
Россия
к. м.н., с. н.с.


И. В. Емельянов
ФГБУ Национальный медицинский исследовательский центр им. В. А. Алмазова.
Россия
к. м.н., с. н.с.


А. О. Недошивин
ФГБУ Национальный медицинский исследовательский центр им. В. А. Алмазова.
Россия
д. м.н., профессор, ученый секретарь.


Список литературы

1. NCD Risk Factor Collaboration Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017; 389: 37–55. doi: 10.1016/S0140-6736(16)31919-5

2. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–223.

3. Chow CK, Teo KK, Rangarajan S, et al., PURE Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959-68. doi: 10.1001/jama.2013.184182

4. Collins R, Peto R, McMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short–term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–838.

5. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014; 114: 1004–1021. doi: 10.1161/ CIRCRESAHA.113.302549

6. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001; 22: 1136–1143.

7. Grassi G, Dell’Oro R, Quarti-Trevano F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005; 48: 1359–1365. doi: 10.1007/s00125-005-1798-z.

8. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995; 96: 1897–1904. doi: 10.1172/JCI118235.

9. Grassi G, Seravalle G, Dell’Oro R, et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000; 36: 538–542.

10. Rumantir MS, Vaz M, Jennings GL, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999; 17: 1125–1133.

11. Julius S, Krause L, Schork NJ, et al. Hyperkinetic borderline hypertension in Tecumseh, Michign. J Hypertens. 1991; 9: 77–84.

12. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension. 1988; 14: 1277–1283.

13. Floras JS, Hara K. Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens. 1993; 11: 647–6

14. Grassi G, Seravalle G, Bertinieri G, et al. Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. J Hypertens. 2000; 18: 587–593.

15. Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001; 38: 1711–1717.

16. Smith PA, Graham LN, Mackintosh AF, et al. Sympathetic neural mechanisms in white-coat hypertension. J Am Coll Cardiol. 2002; 40: 126–132.

17. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003; 108: 560–565. doi: 10.1161/01. CIR.0000081775.72651.B6.

18. Smith PA, Graham LN, Mackintosh AF, et al. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens. 2004; 17: 217–222. doi: 10.1016/j.amjhyper.2003.10.010. 44.

19. Burns J, Sivananthan MU, Ball SG, et al. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007; 115: 1999–2005. doi: 10.1161/CIRCULATIONAHA.106.668863.

20. Grassi G, Seravalle G, Quarti-Trevano F, et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 2009; 53: 205–209. doi: 10.1161/HYPERTENSIONAHA.108.121467.

21. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014; 114: 1804–1814. doi: 10.1161/CIRCRESAHA.114.302524.

22. Bombelli M, Facchetti R, Brambilla G, et al. Clinic, home, 24-hour blood pressure profiles and clinical correlates in resistant hypertension: data from the PAMELA study. J Hypertens. 2012; 30: e53.

23. Brambilla G, Bombelli M, Seravalle G, et al. Prevalence and clinical chrachteristics of patients with true resistant hypertension in central and Eastern Europe: data from PB-CARE study. J Hypertens 2013; 31: 2018-2024. doi: 10.1097/HJH.0b013e328363823f

24. Grassi G., Bombelli M., Buzzi S., et al. Neuroadrenergic disarray in pseudo-resistant and resistant hypertension. Hypertension Research 2014; 37: 479–483. doi: 10.1038/hr.2014.25

25. Calhoun DA, Booth JN 3rd., Oparil S, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014; 63: 451–458. doi: 10.1161/HYPERTENSIONAHA.113.02026.

26. Modolo R, de Faria AP, Sabbatini AR, et al. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015; 9: 397–402. doi: 10.1016/j.jash.2015.03.005.

27. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 2018; 39(Issue 33): 3021–3104. https://doi.org/10.1093/eurheartj/ehy339

28. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34: 2159–2219. doi: 10.1097/HJH.0b013e328364ca4c

29. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313: 603–615. doi: 10.1001/jama.2014.18574

30. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957–967. doi: 10.1016/S0140-6736(15)01225-8

31. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens 2017; 35: 2150–2160. doi: 10.1097/HJH.0000000000001547

32. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015; 33: 1321–1341. doi: 10.1097/HJH.0000000000000614

33. Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited a population-based study. Stroke 2013; 44: 3103–3108. doi: 10.1161/STROKEAHA.113.002329

34. Haim M, Hoshen M, Reges O, et. al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc 2015; 4: e001486. doi: 10.1161/JAHA.114.001486

35. Chugh SS, Havmoeller R, Narayanan K, et.al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129: 837–847. doi: 10.1161/CIRCULATIONAHA.113.005119

36. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6: 213–220. doi: 10.2147/CLEP.S47385

37. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation 2012; 126: e143–146. doi: 10.1161/CIRCULATIONAHA.112.129759

38. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013; 167: 1807–1824. doi: 10.1016/j.ijcard.2012.12.093

39. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N–9N.

40. Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol 2013; 167: 2412–2420. doi: 10.1016/j.ijcard.2013.01.184

41. Oldgren J, Healey JS, Ezekowitz M, et.al. RE-LY Atrial Fibrillation Registry Investigators. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014; 129: 1568–1576. doi: 10.1161/CIRCULATIONAHA.113.005451

42. Chiang CE, Naditch-Brule L, Murin J, et.al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the reallife global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012; 5: 632–639. doi: 10.1161/CIRCEP.112.970749

43. Tverdal A., Hjellvik V., Selmer R. Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379,843 men and women aged 40–45 years. Eur Heart J 2008; 29: 2772– 2781. doi: 10.1093/eurheartj/ehn435

44. Jouven X., Empana JP., Escolano S., et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol 2009; 103: 279-283. doi: 10.1016/j.amjcard.2008.08.071

45. Nauman J., Janszky I., Vatten LJ., Wisloff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011; 306: 2579-2587. doi: 10.1001/jama.2011.1826

46. Kovar D, Cannon CP, Bentley JH, et. al. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol 2004; 27:80–86.

47. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26:967–974.

48. Fox K, Ford I, Steg PG, et. al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817–821. doi: 10.1016/S0140-6736(08)61171-X

49. Fox K, Borer JS, Camm AJ, et. al. Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823–830.

50. Palatini P. Elevated heart rate in cardiovascular diseases: a target to treatment? Prog Cardiovasc Dis 2009; 52: 46–60. doi: 10.1016/j.pcad.2009.05.005

51. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993; 125(4): 1148-1154.

52. Poulter NR, Dobson JE, Sever PS et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009; 54: 1154–61. doi: 10.1016/j.jacc.2009.04.087

53. Okin PM Kjeldsen SE, Julius S, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010; 31: 2271–9. doi: 10.1093/eurheartj/ehq225

54. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012; 109 (5): 685–92. doi: 10.1016/j.amjcard.2011.10.025

55. Saxena A, Minton D, Lee DC, et al. Protective role of resting heart rate on all-cause and cardiovascular disease mortality. Mayo Clin Proc. 2013; 88(12): 1420-6. doi: 10.1016/j.mayocp.2013.09.011


Для цитирования:


Конради А.О., Ратова Л.Г., Емельянов И.В., Недошивин А.О. Роль бета-адреноблокаторов в терапии артериальной гипертензии в рекомендациях ESC/ESH 2018. Российский кардиологический журнал. 2018;(11):96-99. https://doi.org/10.15829/1560-4071-2018-11-96-99

For citation:


Konradi A.O., Ratova L.G., Emelyanov I.V., Nedoshivin A.O. The role of beta-blockers in the treatment of hypertension in 2018 ESC/ESH guidelines. Russian Journal of Cardiology. 2018;(11):96-99. (In Russ.) https://doi.org/10.15829/1560-4071-2018-11-96-99

Просмотров: 356


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)